GREENWICH LIFESCIENCES, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- GREENWICH LIFESCIENCES, INC. payments for repurchase of common stock for the quarter ending 2022-12-31 was $0.00.
- GREENWICH LIFESCIENCES, INC. payments for repurchase of common stock for the quarter ending 2022-09-30 was $0.00.
- GREENWICH LIFESCIENCES, INC. payments for repurchase of common stock for the quarter ending 2022-06-30 was $2.02M.
- GREENWICH LIFESCIENCES, INC. payments for repurchase of common stock for the quarter ending 2022-03-31 was $5.51M.
- GREENWICH LIFESCIENCES, INC. payments for repurchase of common stock for fiscal 2022 was $7.54M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $7.54M 10-K · filed 2024-04-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | |
| 2022-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | |
| 2022-03-31 | $5.51M 10-Q · filed 2022-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |